Ipsen SA
PAR:IPN

Watchlist Manager
Ipsen SA Logo
Ipsen SA
PAR:IPN
Watchlist
Price: 108.6 EUR -0.46% Market Closed
Market Cap: 9.1B EUR
Have any thoughts about
Ipsen SA?
Write Note

Ipsen SA
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Ipsen SA
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Ipsen SA
PAR:IPN
Other Current Liabilities
€757.9m
CAGR 3-Years
23%
CAGR 5-Years
13%
CAGR 10-Years
15%
Sanofi SA
PAR:SAN
Other Current Liabilities
€13.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vetoquinol SA
PAR:VETO
Other Current Liabilities
€9m
CAGR 3-Years
-7%
CAGR 5-Years
14%
CAGR 10-Years
7%
Virbac SA
PAR:VIRP
Other Current Liabilities
€128.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boiron SA
PAR:BOI
Other Current Liabilities
€17.7m
CAGR 3-Years
-36%
CAGR 5-Years
-10%
CAGR 10-Years
-3%
Medincell SA
PAR:MEDCL
Other Current Liabilities
€5.3m
CAGR 3-Years
-1%
CAGR 5-Years
33%
CAGR 10-Years
N/A
No Stocks Found

Ipsen SA
Glance View

Market Cap
9B EUR
Industry
Pharmaceuticals

Ipsen SA, headquartered in France, is a prominent player in the global biopharmaceutical realm, weaving its story through its commitment to innovation and specialization. Founded in 1929, this family-owned company has evolved significantly, utilizing a diverse mix of scientific research and strategic acquisitions to fuel its growth. Ipsen operates through three principal business segments: Specialty Care, Consumer Healthcare, and Research & Development. Specialty Care, which includes oncology, neuroscience, and rare diseases, is the heart of Ipsen's portfolio, contributing the lion's share of its revenue. The company has honed its focus on developing targeted therapies for complex conditions, leveraging its adeptness in peptide and toxin research. Its success lies in the balance of nurturing homegrown research while acquiring promising biotech firms and novel therapies to expand its offerings and market reach. Beyond its scientific and research prowess, Ipsen's financial robustness stems from a well-orchestrated strategy that intertwines its business operations. The company generates substantial revenue by not only launching innovative products but also through strategic partnerships and licensing agreements that broaden its geographic footprint. Ipsen’s Consumer Healthcare segment complements its operations by delivering over-the-counter products that maintain a steady cash flow, though on a smaller scale compared to Specialty Care. Meanwhile, its Research & Development arm remains the crucible for future growth, as Ipsen invests significantly in pioneering future therapies that align with its core areas of expertise. Through this strategic tapestry, Ipsen has positioned itself as a dynamic entity in the biopharmaceutical industry, consistently striving to deliver value while advancing the frontiers of medicine.

IPN Intrinsic Value
151.09 EUR
Undervaluation 28%
Intrinsic Value
Price

See Also

What is Ipsen SA's Other Current Liabilities?
Other Current Liabilities
757.9m EUR

Based on the financial report for Jun 30, 2024, Ipsen SA's Other Current Liabilities amounts to 757.9m EUR.

What is Ipsen SA's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
15%

Over the last year, the Other Current Liabilities growth was -3%. The average annual Other Current Liabilities growth rates for Ipsen SA have been 23% over the past three years , 13% over the past five years , and 15% over the past ten years .

Back to Top